Led by Edward Lin,a medical oncologist at the University of Washington and his collaborators, the study will be the first to specifically target colon cancer stem cells.
The study will apply a combination drug therapy of Capecitabine (a chemotherapy drug) and Celecoxib (an FDA approved arthritis medication)in treating colon cancer stem cells.
Edward Lin said the treatment is offering an immediate benefit to today’s cancer patients.
”95% of participants are out and about in their daily lives, doing what they need to do without skipping a beat,"Lin added.
"The Gateway has provided seed funding that will help this study continue and hopefully help the vision expand so the treatment is available to many more patients."
Out of 124 treated patients, 40% of those treated with this protocol have achieved good progress.